Acta Med. 2009, 52: 3-8

https://doi.org/10.14712/18059694.2016.99

Biological Prognostic Markers in Chronic Lymphocytic Leukemia

Vladimíra Vroblováa, Lukáš Smolejb, Filip Vrbackýb, Karolína Jankovičováa, Monika Hrudkováb, Jaroslav Malýb, Jan Krejseka

aCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Institute of Clinical Immunology and Allergology, Hradec Králové, Czech Republic
bCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, 2nd Department of Internal Medicine, Department of Clinical Hematology, Hradec Králové, Czech Republic

Received February 1, 2009
Accepted April 1, 2009

References

1. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96(6):2240–5.
2. Andreeff M, Darzynkiewicz Z, Sharpless TK, Clarkson BD, Melamed MR. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 1980 (2);55:282–93.
3. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3:401–10. <https://doi.org/10.1038/nrc1093>
4. Caligaris-Cappio F. B-Chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 1996; 87(7):2615–20.
5. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007; 370(9583):230–9. <https://doi.org/10.1016/S0140-6736(07)61125-8>
6. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352:804–815. <https://doi.org/10.1056/NEJMra041720>
7. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin- variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348(18):1764–5. <https://doi.org/10.1056/NEJMoa023143>
8. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94(6):1840–7.
9. Di Raimondo F, Azzaro M, Palumbo G, et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 2001; 15(6):976–80. <https://doi.org/10.1038/sj.leu.2402124>
10. Dighiero G, Binet JL. When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000; 343(24):1799–801. <https://doi.org/10.1056/NEJM200012143432410>
11. Dirix LY, Vermeulen PB, Hubens G, et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 1996; 7(8):843–8. <https://doi.org/10.1093/oxfordjournals.annonc.a010764>
12. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343(26):1910–16. <https://doi.org/10.1056/NEJM200012283432602>
13. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007; 21(1):12–7. <https://doi.org/10.1038/sj.leu.2404441>
14. Duensing S, Atzpodien J. Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymhocytic leukemia cells. Blood 1995; 85:1978–80.
15. Düring J, Naschar M, Schmücker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002; 16:30–5. <https://doi.org/10.1038/sj.leu.2402339>
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1(1):27–31. <https://doi.org/10.1038/nm0195-27>
17. Gasparini G, Harris A. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995; 13:765–82. <https://doi.org/10.1200/JCO.1995.13.3.765>
18. Geisler CH, Philips P, Christensen E, et al. In B-cell chronic lymphocytic leukemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnose patients. Leuk Res 1997; 21:1011–23. <https://doi.org/10.1016/S0145-2126(97)00095-7>
19. Hallek M, Fingerle-Rowson G, Fink AM et al. Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2008;112:Abstract 325.
20. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute– Working Group 1996 guidelines. Blood 2008; 111(12):5446–56. <https://doi.org/10.1182/blood-2007-06-093906> <PubMed>
21. Hamblin T. Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007; 20(3):455–6. <https://doi.org/10.1016/j.beha.2007.02.001>
22. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99:1023–9. <https://doi.org/10.1182/blood.V99.3.1023>
23. Hillmen P, Skotnicki A, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25:5616–23. <https://doi.org/10.1200/JCO.2007.12.9098>
24. Hořejší V, Bartůňková J. Základy imunologie. Triton 2005;95–103.
25. Howard S, Grimaldi JC, Bazan JF, et al. Formation and hydolysis of cyclic ADPribose catalyzed by lymphocyte antigen CD38. Science 1993; 262:1056–9. <https://doi.org/10.1126/science.8235624>
26. Hus I, Podhorecka M, Bojarska-Junak A, et al. The clinical significance of ZAP- 70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006; 17:683–90. <https://doi.org/10.1093/annonc/mdj120>
27. Ibrahim S, Keating M, Do K-A, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98:181–6. <https://doi.org/10.1182/blood.V98.1.181>
28. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000; 14:1414–8. <https://doi.org/10.1038/sj.leu.2401825>
29. Kong GH, Bu JY, Kurosaki T, et al. Reconstitution of Syk function by the ZAP- 70 protein tyrosine kinase. Imunity 1995; 2:485–92. <https://doi.org/10.1016/1074-7613(95)90029-2>
30. Kröber A, Seiler T, Benner A, et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100:1410–16.
31. Letestu R, Rawstron A, Ghia P, et al. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. Clin Cytometry 2006; 70B:309–14. <https://doi.org/10.1002/cyto.b.20132>
32. Li VW, Folkerth RD, Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994; 344:82–6. <https://doi.org/10.1016/S0140-6736(94)91280-7>
33. Lin K, Sherrington PD, Dennis M, et al. Relationship between p53 dysfunction, CD38 expression, and IgVH mutation in chronic lymphocytic leukemia. Blood 2002; 100:1404–9. <https://doi.org/10.1182/blood-2001-11-0066>
34. Maffei R, Marasca R, Martinelli S, et al. Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status. Leukemia 2007; 21(6):1312–5. <https://doi.org/10.1038/sj.leu.2404650>
35. Malavasi J, Funaro A, Roggero S, et al. Human CD38: a glycoprotein in search of a function. Immunol Today 1994; 15:95–7. <https://doi.org/10.1016/0167-5699(94)90148-1>
36. Martinelli S, Maffei R, Castelli I, et al. Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. Leukemia Research 2008; 32(4):493–7. <https://doi.org/10.1016/j.leukres.2007.09.002>
37. Menzel T, Rahman Z, Calleja E. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996; 87:1056–63.
38. Molica S, Cutrona G, Vitelli G, et al. Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early Bcell chronic lymphocytic leukemia. Leukemia Research 2007; 31(11):1575–8. <https://doi.org/10.1016/j.leukres.2007.03.009>
39. Molica S, Vacca A, Ribatti D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002; 100(9): 3344–51. <https://doi.org/10.1182/blood-2002-01-0084>
40. Moreau EJ, Matutes E, A’Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with monoclonal antibody SN 8 (CD79b). Am. J. Clin Pathol 2008; 108:378–82. <https://doi.org/10.1093/ajcp/108.4.378>
41. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008; 22:211–19. <https://doi.org/10.1016/j.blre.2008.03.003>
42. Mustelin T, Taskén K. Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem J 2003; 371:15–27. <https://doi.org/10.1042/bj20021637>
43. Papajík T, Jarošová M, Plachý R, et al. Chronická B-lymfocytární lekémie Část I: Pohled na původ, biologii a genetické změny leukemických buněk. Trans hematol dnes 2006; 12:53–61.
44. Parez-Atayde A, Sallan S, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 15:815–21.
45. Pazzella F, Tse AGD, Cordel JL, et al. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1996; 137(2):225–32.
46. Pepper C, Ward R, Brennan P. Highly purified CD38+ and CD38- sub-clones derived form the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia 2007; 21:687–96. <https://doi.org/10.1038/sj.leu.2404587>
47. Rajkumar S, Fonseca R, Witzig T et al. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 1999; 13:469–72. <https://doi.org/10.1038/sj.leu.2401336>
48. Rassenti L, Neuberg D, Keating M, et al. CD38 compared with ZAP-70 or immunoglobulin mutation status as predictor of disease progression in chronic lymphocytic leukemia. Blood 2004; 104:767.
49. Ribatti D, Vacca A, Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999; 1:293–309. <https://doi.org/10.1038/sj.neo.7900038> <PubMed>
50. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194:1639–47. <https://doi.org/10.1084/jem.194.11.1639> <PubMed>
51. Shanafelt TD, Witzig TE, Fink SR et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24:4634–41. <https://doi.org/10.1200/JCO.2006.06.9492>
52. Schroeder HW, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: Analysis of the antibody repertoire. Immunol Today 1994; 15(6):288–94. <https://doi.org/10.1016/0167-5699(94)90009-4>
53. Schroers R, Griesinger F, Trümper L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005; 19:750–8. <https://doi.org/10.1038/sj.leu.2403707>
54. Smolej L, Andrýs C, Vroblová V. et al. Modern prognostic factors and angiogenesis in chronic lymphocytic leukemia: More data needed. Leukemia Research 2007; 31(12):1763–4. <https://doi.org/10.1016/j.leukres.2007.05.016>
55. Smolej L, Kašparová P. Choice of endothelial marker is crucial for assessment of bone marrow microvessel density in chronic lymphocytic leukemia. APMIS 2008; 116(12):1058–62. <https://doi.org/10.1111/j.1600-0463.2008.00987.x>
56. Stilgenbauer S, Sander S, Bullinger L et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007; 92: 1242–5. <https://doi.org/10.3324/haematol.10720>
57. Tam CS, Otero-Palacios J, Abruzzo LA et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patient. Br J Haematol 2008; 141:36–40. <https://doi.org/10.1111/j.1365-2141.2008.07012.x>
58. Thornton PD, Fernandez C, Giustolisi GM, et al. CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J 2004; 5(2): 145–51. <https://doi.org/10.1038/sj.thj.6200360>
59. Till KJ, Spiller DG, Harris RJ, et al. CLL, but not normal, B cells are dependent on autocrione VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium. Blood 2005; 105(12):4813–19. <https://doi.org/10.1182/blood-2004-10-4054>
60. Toi M, Kondo S, Suzuki H, et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996; 77:1101–6. <https://doi.org/10.1002/(SICI)1097-0142(19960315)77:6<1101::AID-CNCR15>3.0.CO;2-5>
61. Vacca A, Ribatti D, Ruco L, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkins lymphomas. Br J Cancer 1999; 79:965–70. <https://doi.org/10.1038/sj.bjc.6690154> <PubMed>
62. Vrbacky F, Smolej L, Vroblova V, et al. Angiopoietin-2 mRNA expression is increased in patients with chronic lymphocytic leukemia with unmutated IgVH genes. Haematologica 2008; 93[Suppl.1]:535.
63. Wiestner A, Rosenwald A, Barry T, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944–51. <https://doi.org/10.1182/blood-2002-10-3306>
64. Zucchetto A, Bomben R, Dal Bo, et al. ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations. Clin Cytometry 2006; 70B:284–92.
65. Zupo S, Rugari E, Dono M, et al. CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells. Eur J Immunol 1994; 24:1218–22. <https://doi.org/10.1002/eji.1830240532>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive